Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery

Original Research

Published on 21 Feb 2025

MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis

in Experimental Pharmacology and Drug Discovery

Yuanhao Lv
Ying Gao
Wenyu Di
Zhaoyi Li
Yashen Shi
Tianyuan Hou
Yiyang Chen
Jiaqi Tian
Miaoming Xu
Wei Su

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1551863

100 views

Original Research

Published on 20 Feb 2025

The lower rate of bone and joint infection in patients with open extremity fractures associated with vaccination prior to injury: a propensity-matched cohort study

in Experimental Pharmacology and Drug Discovery

Wencheng Hu
Saiyu Shi
Junqing Lin
Tao Gao
Junjie Shen
Yi Sun
Haifeng Wei
Xianyou Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1546191

124 views

Original Research

Accepted on 19 Feb 2025

Resveratrol prevents gallstones in mice fed on a high fat diet via regulating PPAR-γ and SR-BI

in Experimental Pharmacology and Drug Discovery

Menglu Zhao
Boya Xie
Yuxuan Li
Haiqing Dong
Sijia Jiang
Tiantian Zhu
Xiaolong Wu
Chengchen Xu
Jian Zhang
Shiyi Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1543865

Original Research

Accepted on 19 Feb 2025

Green synthesis of silver nanoparticles using Syzygium cumini leaves extract for antibacterial and photodegradation activity

in Experimental Pharmacology and Drug Discovery

Farooq Aziz
Muhammad Imran
Zahid Usman
Qandeel Khalid
Allah Bakhsh Gulshan
Muhammad Naeem Khan
Hafiz Tariq Masood
Muhammad Rafique

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533721

Review

Accepted on 19 Feb 2025

The potential of ARL4C and its-mediated genes in atherosclerosis and agent development

in Experimental Pharmacology and Drug Discovery

Dan Liu
Jingjing Zhao
Jie Wang
Shuangshuang Zhang
Hongfei Jiang
Yudong Wu
Chao Wang
Dongming Xing
Wujun Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1513340

Brief Research Report

Published on 19 Feb 2025

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

in Experimental Pharmacology and Drug Discovery

Petra Molnár
Máté Ágoston Demény
Beáta Várkonyi
Zsuzsanna Polgár
Ágnes Pór
Ilona Kovács
Andrea Szegedi
Attila Gábor Szöllősi
Magdolna Szántó

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1519066

218 views

Original Research

Published on 19 Feb 2025

Harnessing machine learning and AI-driven analytics to identify novel drug targets and predict chemotherapy efficacy in NSCLC

in Experimental Pharmacology and Drug Discovery

Shaojia Qin
Biyu Deng
Dan Mo
Zhengyou Zhang
Xuan Wei
Zhougui Ling

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1555040

256 views

Original Research

Published on 19 Feb 2025

Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head

in Experimental Pharmacology and Drug Discovery

Jie Xu
Wei Deng
Xun Zhu
Deyu Han
Yu Zheng
Qun Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1508971

146 views

Systematic Review

Accepted on 18 Feb 2025

Prognostic and clinicopathological roles of circular RNA expression in chemoresistance in head and neck squamous cell carcinoma: A systematic review

in Experimental Pharmacology and Drug Discovery

Sayan Kumar Das
Sameer Khasbage
Ashim Mishra
Babban Jee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1502107

Original Research

Published on 18 Feb 2025

Mechanism of PAVA-induced toxicity and inflammation in a cocultured skin cell model

in Experimental Pharmacology and Drug Discovery

Yunyang Song
Wenjie Cheng
Zhen Wang
Tianqi Zhou
Fanghui Wu
Yifeng Yin
Dan Xu
Yanli Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531459

111 views

Original Research

Published on 18 Feb 2025

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

in Experimental Pharmacology and Drug Discovery

Qi Yang
Dan Zhao
Linjie Ju
Peng Cao
Jifu Wei
Zhixian Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524277

198 views

Original Research

Accepted on 17 Feb 2025

Adverse event profile of Lomustine and Temozolomide : a descriptive analysis from WHO-VigiAccess

in Experimental Pharmacology and Drug Discovery

Hua Luo
Shaohua Fan
Lu Liang
Youfu He
Jiangjie Chen
Chenghao Xu
Jing Zhu
Liwei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1534802

Original Research

Accepted on 17 Feb 2025

Antimicrobial Photodynamic Therapy with 5-Aminolevulinic Acid plus Antibiotics: A Promising Treatment for Tibial Osteomyelitis Caused by Drug-resistant Bacteria

in Experimental Pharmacology and Drug Discovery

Ju Zuo
Feiyan Kong
Xiyu Wang
Tianyu Wang
Jianxi Zhao
Zhanjuan Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566744

Review

Accepted on 17 Feb 2025

Recent Advances in the Multifaceted Mechanisms of Catalpol in Treating Osteoporosis

in Experimental Pharmacology and Drug Discovery

Na Li
Xiaoying Mu
Shudong Zhang
Huaxin Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1560715

Original Research

Accepted on 17 Feb 2025

FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry

in Experimental Pharmacology and Drug Discovery

Manisha Singh
Shruthi Shanmukha
Raghda Eldesouki
Maged M. Harraz

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1537912

Original Research

Accepted on 17 Feb 2025

Predicting protein-protein interactions in microbes associated with cardiovascular disease using deep denoising autoencoders and evolutionary information

in Experimental Pharmacology and Drug Discovery

Yang Li
Senyu Zhou
Jian Luo
Mei Tang
Chaojun Li
Wenhua He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565860

Navigation group

Articles

MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis

The lower rate of bone and joint infection in patients with open extremity fractures associated with vaccination prior to injury: a propensity-matched cohort study

Resveratrol prevents gallstones in mice fed on a high fat diet via regulating PPAR-γ and SR-BI

Green synthesis of silver nanoparticles using Syzygium cumini leaves extract for antibacterial and photodegradation activity

The potential of ARL4C and its-mediated genes in atherosclerosis and agent development

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

Harnessing machine learning and AI-driven analytics to identify novel drug targets and predict chemotherapy efficacy in NSCLC

Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head

Prognostic and clinicopathological roles of circular RNA expression in chemoresistance in head and neck squamous cell carcinoma: A systematic review

Mechanism of PAVA-induced toxicity and inflammation in a cocultured skin cell model

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

Adverse event profile of Lomustine and Temozolomide : a descriptive analysis from WHO-VigiAccess

Antimicrobial Photodynamic Therapy with 5-Aminolevulinic Acid plus Antibiotics: A Promising Treatment for Tibial Osteomyelitis Caused by Drug-resistant Bacteria

Recent Advances in the Multifaceted Mechanisms of Catalpol in Treating Osteoporosis

FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry

Predicting protein-protein interactions in microbes associated with cardiovascular disease using deep denoising autoencoders and evolutionary information